Rivaroxaban granules for oral suspension was approved by FDA in 2021 for the treatment of venous thromboembolism(VTE) and prevention of VTE recurrence in patients under age of 18 years after at least 5 days of initial parenteral anticoagulation treatment. The development of rivaroxaban granules for oral suspension for pediatric indications was based on adult data. Model-informed drug development method was adopted to support the initial dosage selection in pediatric clinical trials, dose adjustment of phase Ⅱ and Ⅲ clinical trials. This paper analyzes the relative pediatric studies and FDA’s evaluation considerations of rivaroxaban granules for oral suspension, and discusses the application of model-informed drug development in pediatric drug development.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |